Gastroenterology
Volume 138, Issue 2 , Pages 671-681.e2 , February 2010

Silymarin Inhibits In Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection

  • Chihiro Morishima

      Affiliations

    • Division of Virology, Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington
    • Corresponding Author InformationReprint requests Address requests for reprints to: Chihiro Morishima, MD, Department of Laboratory Medicine, University of Washington, Box 359743, Seattle, Washington 98104. fax: (206) 897-4312
    • ,
  • Margaret C. Shuhart

      Affiliations

    • Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Chia C. Wang

      Affiliations

    • Division of Infectious Diseases, Department of Medicine, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Denise M. Paschal

      Affiliations

    • Division of Virology, Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Minjun C. Apodaca

      Affiliations

    • Division of Virology, Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington
    • ,
  • Yanze Liu

      Affiliations

    • Department of Psychiatry, McLean General Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Derek D. Sloan

      Affiliations

    • Division of Virology, Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington
    • Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Tyler N. Graf

      Affiliations

    • Department of Chemistry and Biochemistry, University of North Carolina Greensboro, Greensboro, North Carolina
    • ,
  • Nicholas H. Oberlies

      Affiliations

    • Department of Chemistry and Biochemistry, University of North Carolina Greensboro, Greensboro, North Carolina
    • ,
  • David Y.–W. Lee

      Affiliations

    • Department of Psychiatry, McLean General Hospital, Harvard Medical School, Boston, Massachusetts
    • ,
  • Keith R. Jerome

      Affiliations

    • Division of Virology, Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington
    • Vaccine and Infectious Disease Institute, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Stephen J. Polyak

      Affiliations

    • Division of Virology, Department of Laboratory Medicine, University of Washington School of Medicine, Seattle, Washington
    • Department of Global Health, University of Washington School of Medicine, Seattle, Washington

Received 28 October 2008 ,Accepted 15 September 2009.

References 

  1. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17–35
  2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  3. Fried MW, Shiffman ML, Reddy KR, et al. Peg-interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  4. Davis GL, Albright JE, Cook SF, et al. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl. 2003;9:331–338
  5. Strader DB, Bacon BR, Lindsay KL, et al. Use of complementary and alternative medicine in patients with liver disease. Am J Gastroenterol. 2002;97:2391–2397
  6. Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology. 2008;47:605–612
  7. Agarwal R, Agarwal C, Ichikawa H, et al. Anticancer potential of silymarin: from bench to bedside. Anticancer Res. 2006;26:4457–4498
  8. Polyak SJ, Morishima C, Shuhart MC, et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-κB signaling, and HCV infection by standardized silymarin. Gastroenterology. 2007;132:1925–1936
  9. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61:2035–2063
  10. Jacobs BP, Dennehy C, Ramirez G, et al. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis. Am J Med. 2002;113:506–515
  11. Spengler U, Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond). 2007;112:141–155
  12. Graf TN, Wani MC, Agarwal R, et al. Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention. Planta Med. 2007;73:1495–1501
  13. Morishima C, Polyak SJ, Ray R, et al. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis. 2006;193:931–940
  14. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23:1334–1340
  15. Ghany MG, Kleiner DE, Alter H, et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology. 2003;124:97–104
  16. Schumann J, Prockl J, Kiemer AK, et al. Silibinin protects mice from T cell-dependent liver injury. J Hepatol. 2003;39:333–340
  17. Lee JS, Kim SG, Kim HK, et al. Silibinin polarizes Th1/Th2 immune responses through the inhibition of immunostimulatory function of dendritic cells. J Cell Physiol. 2007;210:385–397
  18. Lorenz D, Lucker PW, Mennicke WH, et al. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol. 1984;6:655–661
  19. Schrieber SJ, Wen Z, Vourvahis M, et al. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos. 2008;36:1909–1916
  20. Hawke RL, Schrieber SJ, Soule TA, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharm. 2009;
  21. Wu JW, Lin LC, Hung SC, et al. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J Pharm Biomed Anal. 2007;45:635–641
  22. Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135:1561–1567

 Conflicts of interest The authors disclose no conflicts.

 Funding Supported by grant R21 AT002895 from the National Center for Complementary and Alternative Medicines/National Institutes of Health (to S.J.P.) and by grant R01 CA104286 from the National Cancer Institute/NIH for the isolation of pure compounds from milk thistle (to T.N.G./N.H.O.); however, study sponsors had no role in the collection, analysis, or interpretation of the data in this manuscript.

PII: S0016-5085(09)01662-X

doi: 10.1053/j.gastro.2009.09.021

Gastroenterology
Volume 138, Issue 2 , Pages 671-681.e2 , February 2010

Article Tools

* Image Usage & Resolution